A new collaboration between Seattle Children's, Children's National Health System, BC Children's Hospital and Children's Hospital Los Angeles is speeding up the development of immunotherapy treatments for childhood cancers and increasing access to clinical trials.
The international collaborative is called CureWorks. Its focus is on expanding immunotherapy trials and patient access around the world and sharing data and collective expertise to advance novel cell therapies. The idea behind CureWorks is that in order to revolutionise treatment for paediatric cancer, academia must come together to achieve better treatments and outcomes for children.
“We believe a unified effort among leading children's hospitals is the best way to drive the discovery of new therapies for paediatric cancer,” said Dr Mike Jensen, Executive Director of CureWorks and Director of the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute. “Our hope is that through this collaboration, we'll be able to more quickly develop treatments with fewer side effects, better remission rates and, ultimately, enable more kids with cancer to grow up and realise their full potential.”